• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Weight Gain From Aripiprazole Same as Risperidone

Weight Gain From Aripiprazole Same as Risperidone

November 21, 2019
Pavan Madan, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Pavan Madan, MD Dr. Madan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Schoemakers RJ et al, J Child Adolesc Psychopharm 2019;29(3):192–196

Many providers prefer aripiprazole over risperidone for young patients due to observed lower incidence of weight gain. This is supported in studies with follow-up of less than 3 months. However, does aripiprazole fare better with long-term use?

Researchers reviewed records of children and adolescents treated with aripiprazole or risperidone for at least 12 months at a Dutch mental health organization between 2008 and 2015. Only 89 of 874 patients on risperidone and 42 on aripiprazole met the inclusion criteria as over 80% of the charts had missing baseline and/or follow-up data.

BMI z-scores (age- and sex-adjusted BMI) significantly increased for both medications over 12 months. The increase was marginally lower for aripiprazole (0.30, 95% CI = 0.07–0.53) than for risperidone (0.37, 95% CI = 0.21–0.53), but not statistically significant (p = 0.97). Of note, the aripiprazole group had a higher BMI-z score at baseline (0.18) compared to the risperidone group (-0.33), possibly as aripiprazole is preferred over risperidone for overweight kids.

The authors predicted that an 11-year-old boy with a BMI of 16.9 at baseline would have a predicted BMI of 18.2 with aripiprazole use for 12 months and 18.4 with risperidone, whereas that same boy would have a BMI of 17.5 without medications for that year.

CCPR’S TAKE
In this study, using aripiprazole to avoid weight gain was fruitless. The small sample size dampens our confidence in the results, but BMI-z scores offer a more accurate understanding of weight gain. If we must use these medications, “old-school” measures like packing lunch for school and eating dinner with the family, plus reducing fast food and screen time, can have an enormous positive impact on a child’s physical and mental ­well-being. Periodic assessment of BMI and metabolic profile should be routine, with dietary counseling and CBT where appropriate. Among pharmacological interventions, adjunctive metformin has the best data, followed by topiramate.
Child Psychiatry
KEYWORDS antipsychotics aripiprazole autism autism-spectrum-disorder risperidone weight-gain
    Pavan Madan, MD

    Why Do So Many Pediatric Antidepressant Research Trials “Fail”?

    More from this author
    www.thecarlatreport.com
    Issue Date: November 21, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Autism in Children and Adolescents, CCPR, November/December 2019
    Note From the Editor-in-Chief
    Exploring the Potential Neurotoxicity of Antipsychotics in Younger Populations
    Managing Irritability in Autism
    Engage Those Infants: Maternal Interaction and Autism
    Heart Rate Changes Linked to ­Emotional Dysregulation
    Weight Gain From Aripiprazole Same as Risperidone
    Crocus Sativus vs Methylphenidate for ADHD
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.